Biotech | December 08, 2021
SPARC partners with Visiox for ophthalmic drugs
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
The product will be commercialized from Unichem's Ghaziabad plant
This further adds to Biocon’s portfolio of vertically integrated complex drug products
The offline store launch will complement the E-commerce website in building a rich consumer shopping experience
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
GreenLight Biosciences is a Boston-based biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible
Flipkart also announced its foray into the healthcare sector through the launch of Flipkart Health+
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Subscribe To Our Newsletter & Stay Updated
